Avalon Globocare Corp :Avalon Globocare Signs Definitive Agreement For Transformational Acquisition Of Leading Laboratory With 2021 Unaudited Revenue In Excess Of $25 Million.Company To Begin Trading Under New Symbol "Albt" On November 10, 2022.Total Consideration For Acquisition Will Be $31 Million.Avalon Globocare - Deal Cash Portion To Be Financed With Private Placement Of $15 Million Of Preferred Stock, Convertible At A Floor Of $1.00 Per Share.Shares Of Co'S Common Stock Will Begin Trading Under New Ticker Symbol "Albt" On Nasdaq Capital Market On Thursday, Nov 10.Sarah Cox, Co-Founder And Ceo Of Laboratory Services, Will Become Chief Operating Officer Of Company.Has Signed A Definitive Acquisition Agreement To Acquire A 60% Interest In Laboratory Services Mso, Llc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。